KBC Group
BCRX icon

KBC Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

KBC Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69K Hold
6,947
– – ﹤0.01% 1594
2026
Q1 		$66K Hold
6,947
– – ﹤0.01% 1538
2025
Q4 		$54K Hold
6,947
– – ﹤0.01% 1611
2025
Q3 		$53K Hold
6,947
– – ﹤0.01% 1627
2025
Q2 		$62K Sell
6,947
-3,251
-32% -$30.3K ﹤0.01% 1482
2025
Q1 		$76K Hold
10,198
– – ﹤0.01% 1624
2024
Q4 		$77K Buy
10,198
+4,537
+80% +$34.4K ﹤0.01% 1691
2024
Q3 		$43K Sell
5,661
-2,974
-34% -$22.6K ﹤0.01% 1765
2024
Q2 		$53K Buy
+8,635
New +$47.7K ﹤0.01% 1579

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

KBC Group's BCRX Position: Q2 2026 in Review

KBC Group held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 6,947 shares worth $69K. The position accounts for ﹤0.01% of the portfolio, ranked #1594.

KBC Group first reported a position in BCRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $77K in Q4 2024. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • KBC Group held 6,947 shares of BioCryst Pharmaceuticals worth $69K as of Q2 2026.
  • KBC Group left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1594 holding.
  • KBC Group first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • KBC Group's BioCryst Pharmaceuticals position peaked at $77K in Q4 2024.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.